<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosley, Mary</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Quyyumi, Arshed A.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%"> PreSERVE-AMI: CD34+ Cells Improve Cardiac Function, Reduce Events after STEMI </style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">24-25</style></pages><abstract><style  face="normal" font="default" size="100%">The intracoronary (IC) infusion of bone marrow mononuclear cells after an STEMI improved cardiac function, including left ventricular ejection fraction, infarct size, and end-systolic volume, and major adverse cardiac events. This article discusses the NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction trial [PreSERVE-AMI; NCT01495364], which looked at IC autologous CD34+ cell therapy for STEMI patients.</style></abstract><number><style face="normal" font="default" size="100%">52</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>